52 results match your criteria Sarcomatoid and Rhabdoid Renal Cell Carcinoma


[Clinicopathological characteristics of fumarate hydratase-deficient renal cell carcinoma].

Zhonghua Bing Li Xue Za Zhi 2019 Feb;48(2):120-126

Department of Pathology, the Affiliated Hospital of Qingdao University, Qingdao 266003, China.

To investigate the clinicopathologic characteristics, molecular and genetic features, differential diagnoses and prognosis of fumarate hydratase-deficient renal cell carcinoma (FH-RCC). The immunohistochemical (IHC) expression of FH in 391 renal neoplasms in tissue chips collected from the Affiliated Hospital of Qingdao University and 971 Hospital of PLA Navy from January 2011 to December 2017 was evaluated. The clinicopathologic data of eight FH negative cases were collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0529-5807.2019.02.009DOI Listing
February 2019
13 Reads

Grading of renal cell carcinoma.

Histopathology 2019 Jan;74(1):4-17

Aquesta Uropathology, Brisbane, Qld, Australia.

Grading of renal cell carcinoma (RCC) has been recognised as a prognostic factor for almost 100 years. Numerous grading systems have been proposed, initially focusing upon a constellation of cytological features and more recently on nuclear morphology. It has been recommended that grading of RCC should be based upon nucleolar prominence/eosinophilia for grades 1-3, while grade 4 requires nuclear anaplasia (including tumour giant cells, sarcomatoid differentiation and/or rhabdoid morphology). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.13735DOI Listing
January 2019
3 Reads

Implications of Programmed Death Ligand-1 Positivity in Non-Clear Cell Renal Cell Carcinoma.

J Kidney Cancer VHL 2018 13;5(4):6-13. Epub 2018 Oct 13.

Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

The purpose of this study was to assess the prognostic value of programmed death ligand-1 (PD-L1) positivity in a non-clear cell renal cell carcinoma (non-ccRCC) cohort. PD-L1 expression was evaluated by immunohistochemistry (IHC) using formalin-fixed paraffin-embedded (FFPE) specimens from 45 non-ccRCC patients with available tissue. PD-L1 positivity was defined as ≥1% of staining. Read More

View Article

Download full-text PDF

Source
http://jkcvhl.com/index.php/jkcvhl/article/view/107
Publisher Site
http://dx.doi.org/10.15586/jkcvhl.2018.107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186848PMC
October 2018
9 Reads

Data set for the reporting of carcinoma of renal tubular origin: recommendations from the International Collaboration on Cancer Reporting (ICCR).

Histopathology 2019 Feb;74(3):377-390

Department of Pathology, NYU Langone Medical Center, New York, NY, USA.

Aims: The International Collaboration on Cancer Reporting (ICCR) has provided detailed data sets based upon the published reporting protocols of the Royal College of Pathologists, the Royal College of Pathologists of Australasia and the College of American Pathologists.

Methods And Results: The data set for carcinomas of renal tubular origin treated by nephrectomy was developed to provide a minimum structured reporting template suitable for international use, and incorporated recommendations from the 2012 Vancouver Consensus Conference of the International Society of Urological Pathology (ISUP) and the fourth edition of the World Health Organisation Bluebook on tumours of the urinary and male genital systems published in 2016. Reporting elements were divided into those, which are required and recommended components of the report. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.13754DOI Listing
February 2019
5 Reads

[Renal cell carcinoma with sarcomatoid and rhabdoid features: a clinico-pathological series of 74 cases].

An Sist Sanit Navar 2018 Aug 29;41(2):191-199. Epub 2018 Aug 29.

Hospital San Jorge, Huesca.

Objetives. Our aim is to analyze and compare the clinico-pathological features in renal cell carcinomas (RCC) with sarcomatoid and rhaboid phenotype.

Material And Methods: We reviewed consecutive patients with nephrectomy RCC from January 1988 to January 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23938/ASSN.0306DOI Listing
August 2018
10 Reads

The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.

Cancer Immunol Res 2018 07 10;6(7):758-765. Epub 2018 May 10.

Dana-Farber Cancer Institute, Boston, Massachusetts.

Programmed death 1 (PD-1) and PD ligand 1 (PD-L1) inhibitors have shown activity in metastatic clear cell renal cell carcinoma (ccRCC). Data on the activity of these agents in patients with non-clear cell RCC (nccRCC) or patients with sarcomatoid/rhabdoid differentiation are limited. In this multicenter analysis, we explored the efficacy of PD-1/PD-L1 inhibitors in patients with nccRCC or sarcomatoid/rhabdoid differentiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-17-0475DOI Listing
July 2018
30 Reads

Verification of the International Society of Urological Pathology recommendations in Japanese patients with clear cell renal cell carcinoma.

Int J Oncol 2018 Apr 28;52(4):1139-1148. Epub 2018 Feb 28.

Department of Urology, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan.

The aim of the present study was to evaluate the validity of potential prognostic parameters of clear cell renal cell carcinoma (ccRCC) recommended by the 2012 International Society of Urological Pathology (ISUP) Consensus Conference in the Japanese population. We reviewed 406 Japanese patients with localized or locally advanced ccRCC who underwent curative surgery during 2004-2014 at Tokai University Hospital (Isehara, Japan) and were followed up for >2 years after surgery. A single pathologist reviewed all the histological slides. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2018.4294DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843402PMC
April 2018
11 Reads

Pattern multiplicity and fumarate hydratase (FH)/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration.

Mod Pathol 2018 06 6;31(6):974-983. Epub 2018 Feb 6.

Réseau National pour Cancers Rares de l'Adulte PREDIR AP-HP labellisé par l'Institut National du Cancer (INCa), Hôpital de Bicêtre, 94275, Le Kremlin Bicêtre, France.

Hereditary leiomyomatosis and renal cell carcinoma syndrome is characterized by an increased risk of agressive renal cell carcinoma, often of type 2 papillary histology, and is caused by FH germline mutations. A prominent eosinophilic macronucleolus with a perinucleolar clear halo is distinctive of hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cell carcinoma according to the 2012 ISUP and 2016 WHO kidney tumor classification. From an immunohistochemistry perspective, tumors are often FH-negative and S-(2-succino)-cysteine (2SC) positive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41379-018-0017-7DOI Listing
June 2018
19 Reads

Architectural Patterns are a Relevant Morphologic Grading System for Clear Cell Renal Cell Carcinoma Prognosis Assessment: Comparisons With WHO/ISUP Grade and Integrated Staging Systems.

Am J Surg Pathol 2018 04;42(4):423-441

University Paris Diderot, INSERM, IAME, UMR_1137, Paris.

We developed and validated an architecture-based grading for clear cell renal cell carcinoma (ccRCC) in an observational retrospective cohort study including 506 tumors (principal cohort, n=254; validation cohort, n=252). Study endpoints were disease-free survival (DFS) and cancer-specific survival (CSS). Relationships with outcome were analyzed using Harrell concordance index, time-dependent receiver operating characteristic curve, area under curve, and Cox regression model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000001025DOI Listing
April 2018
8 Reads

Renal cell carcinoma, unclassified with medullary phenotype: poorly differentiated adenocarcinomas overlapping with renal medullary carcinoma.

Hum Pathol 2017 09 15;67:134-145. Epub 2017 Jul 15.

Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA; Department of Pathology and Laboratory Medicine, University of Tennessee Health Sciences, Memphis, TN, 38163, USA. Electronic address:

Renal medullary carcinoma (RMC) is a highly aggressive renal cell carcinoma arising in the collecting system and requiring careful correlation with status of sickle cell trait. A panel of international experts has recently proposed provisional diagnostic terminology, renal cell carcinoma, unclassified, with medullary phenotype, based on encountering an extraordinarily rare tumor with RMC morphology and immunophenotype in an individual proven not to have a hemoglobinopathy. Herein, we extend this observation to a cohort of 5 such tumors, morphologically similar to RMC, lacking SMARCB1 expression by immunohistochemistry, but each without evidence of a hemoglobinopathy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2017.07.006DOI Listing
September 2017
11 Reads

Adverse pathologic characteristics in the small renal mass: implications for active surveillance.

Can J Urol 2017 Apr;24(2):8759-8764

Department of Urology, Yale School of Medicine, New Haven, Connecticut, USA.

Introduction: Evidence has demonstrated that tumor size is related to adverse oncologic outcomes in small renal tumors (≤ 4 cm). We evaluated the association of adverse pathologic features (APF) with tumor size and survival in patients with a small renal mass (SRM).

Materials And Methods: We retrospectively reviewed the pathologic characteristics of 380 surgically resected SRMs from a single institution. Read More

View Article

Download full-text PDF

Source
April 2017
13 Reads

Rapidly Growing Right Ventricular Outflow Tract Mass in Patient with Sarcomatoid Renal Cell Carcinoma.

J Cardiovasc Ultrasound 2016 Dec 28;24(4):329-333. Epub 2016 Dec 28.

Department of Internal Medicine, Cardiovascular Center, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea.

Cardiac metastasis from renal cell carcinoma (RCC) without inferior vena cava (IVC) involvements is extremely rare with few reported cases. Sarcomatoid RCC with rhabdoid feature is a rare pathologic type of RCC having aggressive behavior due to great metastatic potential. Here, we report a case of rapidly growing cardiac metastasis of RCC which brought on right ventricular outflow tract (RVOT) obstruction without IVC and right atrial involvement in a 61-year-old woman. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4250/jcu.2016.24.4.329DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5234337PMC
December 2016
11 Reads

Acquired cystic disease-associated renal cell carcinoma: a clinicopathological study of seven cases.

Pol J Pathol 2017;68(4):306-311

The disease entity of acquired cystic disease (ACD)-associated renal cell carcinoma (RCC) has been recently incorporated into the international renal tumor classification. However, there are a few descriptions on clinicopathologic features. We performed a clinicopathologic study of seven cases with ACD-RCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/pjp.2017.73926DOI Listing
June 2018
6 Reads

Re: Daniel M. Geynisman. Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features. Eur Urol 2015;68:912-4.

Eur Urol 2017 01 11;71(1):e27-e28. Epub 2016 Jul 11.

Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2016.06.039DOI Listing
January 2017
10 Reads

Re: Francesco Piva, Matteo Santoni, Marina Scarpelli, et al's Letter to the Editor re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912-4.

Eur Urol 2017 01 11;71(1):e26. Epub 2016 Jul 11.

Servizo de Oncoloxía Médica, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain; Instituto de Investigación Sanitaria de Santiago de Compostela, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2016.06.038DOI Listing
January 2017
12 Reads

[The WHO/ISUP grading system for renal carcinoma].

Authors:
H Moch

Pathologe 2016 Jul;37(4):355-60

Institut für Pathologie und Molekularpathologie, UniversitätsSpital Zürich, Schmelzbergstrasse 12, 8091, Zürich, Schweiz.

Histological tumor grading is an accepted prognostic parameter of renal cell carcinoma (RCC). In 2012, the International Society of Urologic Pathologists (ISUP) proposed a novel grading system for RCC, mainly based on the evaluation of nucleoli: grade 1 tumors have nucleoli that are inconspicuous and basophilic at ×400 magnification; grade 2 tumors have nucleoli that are clearly visible at ×400 magnification and eosinophilic; grade 3 tumors have clearly visible nucleoli at ×100 magnification; and grade 4 tumors have extreme pleomorphism or rhabdoid and/or sarcomatoid morphology. This grading system was validated for clear cell renal cell carcinoma and papillary renal cell carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00292-016-0171-yDOI Listing
July 2016
11 Reads

Prognostic implications of sarcomatoid and rhabdoid differentiation in patients with grade 4 renal cell carcinoma.

Int Urol Nephrol 2016 Aug 23;48(8):1253-1260. Epub 2016 May 23.

Glickman Urological and Kidney Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44016, USA.

Objective: Sarcomatoid and rhabdoid differentiation are associated with poor outcomes in renal cell carcinoma (RCC). We examined the impact of differentiation on cancer-specific survival (CSS) in surgically treated patients with grade 4 RCC.

Materials And Methods: Using our institutional database of 1176 nephrectomies from 2005 to 2013, we identified patients with grade 4 RCC or any grade and the presence of sarcomatoid or rhabdoid differentiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11255-016-1314-zDOI Listing
August 2016
36 Reads
1 Citation
1.293 Impact Factor

Targeted Therapy for Renal Cell Carcinoma.

Authors:
R Joshi S Rawal

JNMA J Nepal Med Assoc 2015 Apr-Jun;53(198):83-8

Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India.

Introduction: Our study aims to evaluate the use of targeted therapy in metastatic renal cell carcinoma Methods: This is a prospective study done over three years from December 2010 to December, 2013.Out of Forty seven patients of metastatic renal cell carcinoma 8(neo-adjuvant cases) were excluded and 39 were included in this study. All patients received Tyrosine kinase inhibitor, sunitinib therapy (50 mg OD, 4/2 scheme). Read More

View Article

Download full-text PDF

Source
November 2017
11 Reads

Renal Neoplasms With Overlapping Features of Clear Cell Renal Cell Carcinoma and Clear Cell Papillary Renal Cell Carcinoma: A Clinicopathologic Study of 37 Cases From a Single Institution.

Am J Surg Pathol 2016 Feb;40(2):141-54

Robert J Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH.

Clear cell papillary renal cell carcinoma (CCPRCC) was recently included in the International Society of Urological Pathology Vancouver Classification of Renal Neoplasia as a subtype of RCC that is morphologically, immunohistochemically, and genetically distinct from both clear cell renal cell carcinoma (CCRCC) and papillary renal cell carcinoma. In our clinical practice we have observed tumors with overlapping histologic features of CCPRCC and CCRCC; therefore, our aim was to describe the morphologic, immunohistochemical, and clinical characteristics of these tumors. We examined a large series of consecutive nephrectomies diagnosed as CCRCC and found 37 tumors with morphologic overlap between CCRCC and CCPRCC, identifying 2 patterns. Read More

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/ajsp/2016/02000/Renal_Neoplasms
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/PAS.0000000000000583DOI Listing
February 2016
32 Reads

Gleason and Fuhrman no longer make the grade.

Histopathology 2016 Mar 16;68(4):475-81. Epub 2015 Nov 16.

Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.

Grading is an important prognostic parameter for prostate adenocarcinoma and renal cell carcinoma (RCC); however, the most frequently used classifications fail to account for advances in our understanding of the diagnostic features, classification and/or behaviour of these tumours. In 2005 and 2014, the International Society of Urological Pathology (ISUP) proposed changes to Gleason scoring with the adoption of the ISUP grading for prostate cancer in 2014 (grade 1, score 3 + 3; grade 2, score 3 + 4; grade 3, score 4 + 3; grade 4, score 8; grade 5, score 9-10). Internationally the Fuhrman grading system is widely employed despite criticisms related to its application, validity, and reproducibility. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.12803DOI Listing
March 2016
35 Reads

Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features.

Eur Urol 2015 Nov 18;68(5):912-4. Epub 2015 Jul 18.

Department of Hematology/Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2015.07.008DOI Listing
November 2015
12 Reads

[Renal cell carcinoma: pathological prognostic factors, staging and histopathological classification of 355 cases].

Rev Med Inst Mex Seguro Soc 2015 Jul-Aug;53(4):454-65

Servicio de Anatomía Patológica, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Distrito Federal, México.

Background: New morphologic entities for Renal Cell Carcinoma (RCC) that influence the prognosis have been described. Clinical staging has also undergone several modifications, the last one published in 2010 7th edition of the American Joint Committee on Cancer. The aim of this article is to determine the prevalence of histological subtypes, Fuhrman grading and clinical staging of renal cell carcinomas. Read More

View Article

Download full-text PDF

Source
January 2017
25 Reads

Review of renal cell carcinoma with rhabdoid features with focus on clinical and pathobiological aspects.

Pol J Pathol 2015 Mar;66(1):3-8

Naoto Kuroda MD, Department of Pathology, Kochi Red Cross Hospital, Shin-honmachi 2-13-51, Kochi City,, Kochi 780-8562, Japan, tel. +81-88-822-1201, fax +81-88-822-1056, e-mail:

Rhabdoid morphology in renal cell carcinoma (RCC) may, like sarcomatoid change, be perceived as a type of dedifferentiation, and is a poor prognostic factor. Histologically, rhabdoid neoplastic cells are round to polygonal cells with globular eosinophilic cytoplasmic inclusions and eccentric vesicular nuclei and enlarged nucleoli. All types of RCC, including clear cell, papillary, chromophobe, collecting duct carcinoma, renal medullary carcinoma, acquired cystic disease-associated RCC, ALK-positive renal cancer and unclassified RCC, may display a variably prominent rhabdoid phenotype. Read More

View Article

Download full-text PDF

Source
March 2015
11 Reads

Outcome prediction for patients with renal cell carcinoma.

Semin Diagn Pathol 2015 Mar 7;32(2):172-83. Epub 2015 Feb 7.

Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First St, Southwest Rochester, Minnesota 55905. Electronic address:

Outcome assessment for renal cell carcinoma is somewhat controversial. Despite numerous studies, a very limited variety of features have been recognized as having prognostic significance in clinical practice. In this review, tumor features considered to be of importance in outcome prediction for surgically treated patients with the 3 most commonly encountered morphotypes of renal cell carcinoma (clear cell, papillary, and chromophobe renal cell carcinoma) are evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.semdp.2015.02.008DOI Listing
March 2015
19 Reads

Adult renal cell carcinoma with rhabdoid differentiation: incidence and clinicopathologic features in Chinese patients.

Ann Diagn Pathol 2015 Apr 2;19(2):57-63. Epub 2015 Feb 2.

Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing, China.

Renal cell carcinoma (RCC) with rhabdoid differentiation is a recently described variant of RCC, which has seldom been reported in China. This form of differentiation has been generally associated with a poor prognosis and is often present in tumors with a poorly differentiated morphology. The development of a rhabdoid morphology appears to represent a common dedifferentiation pathway for renal parenchymal malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anndiagpath.2015.01.006DOI Listing
April 2015
38 Reads

Impact of Rhabdoid Differentiation on Prognosis for Patients with Grade 4 Renal Cell Carcinoma.

Eur Urol 2015 Jul 28;68(1):5-7. Epub 2015 Jan 28.

Department of Oncology, Mayo Clinic, Rochester, MN, USA. Electronic address:

Renal cell carcinoma (RCC) with rhabdoid differentiation is thought to portend a poor prognosis, similar to RCC with sarcomatoid differentiation. Both features are currently classified as grade 4 RCC based on the most recent International Society of Urological Pathology (ISUP) grading system. We reviewed a large series of patients with grade 4 RCC to determine the differential effects of rhabdoid and sarcomatoid differentiation on patient outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2015.01.002DOI Listing
July 2015
14 Reads

[Vancouver classification of renal tumors: Recommendations of the 2012 consensus conference of the International Society of Urological Pathology (ISUP)].

Pathologe 2015 May;36(3):310-6

Institut für Pathologie, Universitätsklinikum Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Deutschland,

The 2012 consensus conference of the International Society of Urological Pathology (ISUP) has formulated recommendations on classification, prognostic factors and staging as well as immunohistochemistry and molecular pathology of renal tumors. Agreement was reached on the recognition of five new tumor entities: tubulocystic renal cell carcinoma (RCC), acquired cystic kidney disease-associated RCC, clear cell (tubulo) papillary RCC, microphthalmia transcription factor family RCC, in particular t(6;11) RCC and hereditary leiomyomatosis-associated RCC. In addition three rare forms of carcinoma were considered as emerging or provisional entities: thyroid-like follicular RCC, succinate dehydrogenase B deficiency-associated RCC and anaplastic lymphoma kinase (ALK) translocation RCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00292-014-2030-zDOI Listing
May 2015
25 Reads

Renal cell carcinoma with rhabdoid and sarcomatoid features presented as a metastatic thigh mass with an unusual immunohistochemical profile.

Rare Tumors 2014 Jan 18;6(1):5037. Epub 2014 Mar 18.

Department of Pathology, Faculty of Medicine, Menofiya University , Shebein Elkom, Egypt.

Renal cell carcinoma (RCC) may metastasize anywhere in the body and sometimes the primary tumor is missing and necessitates extensive investigations to detect. In this report, we describe a case of RCC metastasizing to the thigh in a 70 year old male with a highly pleomorphic morphology suggesting a high grade sarcoma that showed unequivocal positivity for desmin directing the diagnosis for pleomorphic rhabdomyosarcoma. After completion of 33 cycles of radiotherapy, the patient developed large intraabdominal mass that showed conventional areas of RCC with immunoreactivity for CD10, CK, EMA, carbonic anhydrase IX and vimentin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4081/rt.2014.5037DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977166PMC
January 2014
7 Reads

Advances in renal neoplasia: recommendations from the 2012 International Society of Urological Pathology Consensus Conference.

Urology 2014 May 22;83(5):969-74. Epub 2014 Mar 22.

Department of Oncology-Pathology, Karolinska University Hospital, Solna, Stockholm, Sweden.

The International Society of Urological Pathology (ISUP) 2012 Consensus Conference made recommendations regarding the classification, prognostic factors, staging, and immunohistochemical and molecular assessment of adult renal tumors. There was consensus that 5 entities should be recognized as novel tumors: tubulocystic renal cell carcinoma (RCC), acquired cystic disease-associated RCC, clear cell papillary RCC, microphthalmia transcription factor-family translocation RCC [in particular t(6; 11) RCC], and hereditary leiomyomatosis RCC syndrome-associated RCC. In addition, 3 rare epithelial carcinomas were considered emerging or provisional entities: thyroid-like follicular RCC, succinate dehydrogenase B deficiency-associated RCC, and anaplastic lymphoma kinase translocation RCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2014.02.004DOI Listing
May 2014
10 Reads

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC): a rapid autopsy report of metastatic renal cell carcinoma.

Am J Surg Pathol 2014 Apr;38(4):567-77

Departments of *Pathology #Urology †Internal Medicine, Division of Hematology and Oncology ‡Comprehensive Cancer Center, University of Michigan Health System ∥Michigan Center for Translational Pathology ¶Howard Hughes Medical Institute, Ann Arbor, MI §Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY.

Rapid ("warm") autopsies of patients with advanced metastatic cancer provide invaluable insight into the natural history, pathobiology, and morphology of advanced and treatment-resistant tumors. Here, we report a rapid autopsy case of a hereditary leiomyomatosis and renal cell carcinoma (HLRCC) patient with advanced metastatic renal cell carcinoma (RCC)-the first such case described for either a primary renal tumor or HLRCC-related cancer. Mutations in the fumarate hydratase (FH) gene underlie HLRCC, a rare syndrome involving cutaneous and uterine leiomyomata and aggressive kidney tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000127DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117250PMC
April 2014
27 Reads

Sarcomatoid renal cell carcinoma with rhabdoid features.

Ann Saudi Med 2013 Sep-Oct;33(5):495-9

Dr. Mohammed Akhtar, King Faisal Specialist Hospital and Research Center, Pathology & Laboratory Medicine, DPLM, MBC 10 PO Box 3354 Riyadh 11211 Saudi Arabia, T: +966-11-4424280, F: +966-11-4424280,

Sarcomatoid renal cell carcinoma (SRCC) with rhabdoid features is a rare tumor with aggressive behavior and poor prognosis. We report a case of a 71-year-old man with a large left-sided renal mass. Nephrectomy specimen revealed clear cell carcinoma with sarcomatoid and rhabdoid tumor cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5144/0256-4947.2013.495DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074894PMC
August 2014
4 Reads

The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters.

Am J Surg Pathol 2013 Oct;37(10):1490-504

*Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand †Department of Pathology, Mayo Clinic, Rochester, MN §Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO ∥Department of Anatomic Pathology, Cancer Biology and Glickman Urological Institute, Cleveland, OH ††Department of Pathology, Indiana University School of Medicine, Indianapolis, IN ‡Dipartimento di Patologia e Diagnostica, Universitá di Verona, Verona ‡‡The Institute of Pathological Anatomy and Histopathology, University of Ancona School of Medicine, Ancona, Italy ¶Department of Oncology and Pathology, Karolinska University Hospital, Solna, Stockholm, Sweden #Department of Pathology, Fundacion Puigvert-University Antonomous, Barcelona, Spain **University of Zurich, Switzerland §§Department of Laboratory Medicine, Credit Valley Hospital, Mississauga ∥∥Department of Pathology and Molecular Medicine, McMaster University, Toronto, ON, Canada.

The International Society of Urological Pathology 2012 Consensus Conference made recommendations regarding classification, prognostic factors, staging, and immunohistochemical and molecular assessment of adult renal tumors. Issues relating to prognostic factors were coordinated by a workgroup who identified tumor morphotype, sarcomatoid/rhabdoid differentiation, tumor necrosis, grading, and microvascular invasion as potential prognostic parameters. There was consensus that the main morphotypes of renal cell carcinoma (RCC) were of prognostic significance, that subtyping of papillary RCC (types 1 and 2) provided additional prognostic information, and that clear cell tubulopapillary RCC was associated with a more favorable outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0b013e318299f0fbDOI Listing
October 2013
93 Reads

Extensive peritoneal carcinomatosis secondary to renal cell carcinoma with sarcomatoid and rhabdoid differentiation.

BMJ Case Rep 2013 Apr 22;2013. Epub 2013 Apr 22.

Department of Pathology, Howard University Hospital, Washington, District of Columbia, USA.

Renal cell carcinoma (RCC), the most common malignancy of kidney, originates from renal tubular epithelium. It is subclassified based on histological and molecular features. Rarely, RCC can show focal to extensive sarcomatoid or rhabdoid differentiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2013-008725DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645629PMC
April 2013
6 Reads

Multiple cytokeratin-negative malignant tumors composed only of rhabdoid cells in the renal pelvis: a sarcomatoid urothelial carcinoma?

Authors:
Tadashi Terada

Int J Clin Exp Pathol 2013 15;6(4):724-8. Epub 2013 Mar 15.

Department of Pathology, Shizuoka City Shimizu Hospital, Shizuoka, Japan.

The author presents a unique case of multiple cytokeratin-negative malignant tumors consisting only of rhabdoid cells in the renal pelvis. A 54-year-old man complained of hematuria. A transurethral endoscopic examination revealed multiple papillary tumors, and transurethral resection of the bladder tumors was performed. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3606863PMC
October 2013
6 Reads

Expression of angiogenesis-related gene profiles and development of resistance to tyrosine-kinase inhibitor in advanced renal cell carcinoma: characterization of sorafenib-resistant cells derived from a cutaneous metastasis.

Int J Urol 2013 Sep 4;20(9):923-30. Epub 2013 Feb 4.

Department of Urology, Kochi University, Nankoku City, Japan.

Objectives: To investigate the potential mechanism of development of resistance to tyrosine kinase inhibitor in renal cell carcinoma.

Methods: A primary culture of renal cell carcinoma cells (KMRM-S2) was established from an advanced renal cell carcinoma patient with cutaneous metastasis, who had not responded to sorafenib. A total of 84 human angiogenesis-related genes were compared between cutaneous metastasis and the primary tumor by real time polymerase chain reaction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/iju.12084DOI Listing
September 2013
4 Reads

A novel grading system for clear cell renal cell carcinoma incorporating tumor necrosis.

Am J Surg Pathol 2013 Mar;37(3):311-22

Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand.

Grading of renal cell carcinoma (RCC) has prognostic significance, and there is recent consensus by the International Society of Urological Pathology (ISUP) that for clear cell and papillary RCC, grading should primarily be based on nucleolar prominence. Microscopic tumor necrosis also predicts outcome independent of tumor grading. This study was undertaken to assess whether the incorporation of microscopic tumor necrosis into the ISUP grading system provides survival information superior to ISUP grading alone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0b013e318270f71cDOI Listing
March 2013
22 Reads

Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method.

Cancer 2012 Sep 17;118(18):4427-36. Epub 2012 Jan 17.

Japanese Foundation for Cancer Research, Tokyo, Japan.

Background: Several promising molecular-targeted drugs are used for advanced renal cancers. However, complete remission is rarely achieved, because none of the drugs targets a key molecule that is specific to the cancer, or is associated with "oncogene addiction" (dependence on one or a few oncogenes for cell survival) of renal cancer. Recently, an anaplastic lymphoma kinase (ALK) fusion, vinculin-ALK, has been reported in pediatric renal cell carcinoma (RCC) cases who have a history of sickle cell trait. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.27391
Publisher Site
http://dx.doi.org/10.1002/cncr.27391DOI Listing
September 2012
9 Reads

Adult renal cell carcinoma with rhabdoid morphology represents a neoplastic dedifferentiation analogous to sarcomatoid carcinoma.

Ann Diagn Pathol 2011 Oct 12;15(5):333-7. Epub 2011 Jun 12.

Department of Pathology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, FL 33138, USA.

Renal cell carcinoma (RCC) with rhabdoid morphology (RCC-RM) is a recently described variant of RCC, which has an aggressive biologic behavior and poor prognosis, akin to sarcomatoid RCC. The current World Health Organization classification of RCC does not include the rhabdoid phenotype as a distinct histologic entity. The aim of this study is to investigate whether RCC-RM represents a dedifferentiation of a classifiable-type World Health Organization RCC or a carcinosarcoma with muscle differentiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anndiagpath.2011.03.002DOI Listing
October 2011
10 Reads

Re-evaluation of histological type by immunohistochemical and genetic study of transcription factors (TFE3 and TFEB) of VHL gene mutation-negative clear cell renal cell carcinoma and other special types of renal tumor.

Med Mol Morphol 2011 Mar 23;44(1):46-51. Epub 2011 Mar 23.

Department of Diagnostic Pathology, Kochi Red Cross Hospital, 2-13-51 Shin-honmachi, Kochi, 780-8562, Japan.

Translocation-type renal carcinoma has been recently discovered, and it is possible that this tumor may have been previously diagnosed as other types of renal tumor. We have subjected 41 renal tumors, including VHL gene mutation-negative clear cell renal cell carcinoma (RCC), papillary RCC, and chromophobe RCC, to immunohistochemistry of transcription factor E3 (TFE3) and TFEB. All tumors were histologically evaluated by additional immunohistochemical study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00795-009-0478-3DOI Listing
March 2011
18 Reads

Acquired cystic disease-associated renal cell carcinoma with sarcomatoid change and rhabdoid features.

Ann Diagn Pathol 2011 Dec 30;15(6):462-6. Epub 2010 Oct 30.

Department of Diagnostic Pathology, Kochi Red Cross Hospital, Kochi 780-8562, Japan.

Acquired cystic disease (ACD)-associated renal cell carcinoma (RCC) is a recently described entity. To the best of our knowledge, there are no reports of ACD-associated RCC with sarcomatoid and rhabdoid changes. In this article, we present the first case of such a tumor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anndiagpath.2010.07.008DOI Listing
December 2011
6 Reads

The significance of florid giant cell component in renal cell carcinoma: a case report and review of the literature.

Can J Urol 2010 Jun;17(3):5219-22

Department of Laboratory Medicine, and the Keenan Research Centre in the Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Ontario, Canada.

Background: Renal cell carcinoma (RCC) with multinucleated giant cells has been reported in the literature. Different types of multinucleated giant cells have been described, including the osteoclast-like giant cells, rhabdoid cells, syncytial giant cells and tumor multinucleated giant cells.

Results: We describe a unique case of a clear cell RCC with extensive giant cell component. Read More

View Article

Download full-text PDF

Source
June 2010
5 Reads

[Renal cell carcinoma with rhabdoid features and sarcomatoid change: a case report].

Hinyokika Kiyo 2010 Apr;56(4):221-3

Department of Urology, Kochi University School of Medicine.

In Feb 2009, a-54-year-old female complained of left flank pain and macrohematuria. Computed tomography (CT) demonstrated the left renal tumor. In Mar 2009, she was referred to our hospital. Read More

View Article

Download full-text PDF

Source
April 2010
8 Reads

High-grade urothelial carcinoma of the renal pelvis: clinicopathologic study of 108 cases with emphasis on unusual morphologic variants.

Mod Pathol 2006 Apr;19(4):494-503

Department of Pathology, Ohio State University Medical Center, The Ohio State University, University Hospital, Columbus, OH 43210, USA.

A clinicopathologic study of 108 cases of high-grade urothelial carcinomas of the renal pelvis is presented. Of the 108 tumors, 44 (40%) showed unusual morphologic features, including micropapillary areas (four cases), lymphoepithelioma-like carcinoma (two cases), sarcomatoid carcinoma (eight cases, including pseudoangiosarcomatous type), squamous differentiation and squamous cell carcinoma (15 cases), clear cells (two cases), glandular differentiation (two cases), rhabdoid, signet-ring or plasmacytoid cells (four cases), pseudosarcomatous stromal changes (four cases) and intratubular extension into the renal pelvis (three cases). Pathological staging was available in 62 patients; of these, 46 cases (74%) were in high stage (pT2-pT4) and 16 (26%) were in low stage (pTis, pTa, pT1). Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/3800559
Publisher Site
http://dx.doi.org/10.1038/modpathol.3800559DOI Listing
April 2006
13 Reads

Urothelial carcinoma with rhabdoid features: report of 6 cases.

Hum Pathol 2006 Feb;37(2):168-72

Department of Pathology, University of Pittsburgh Medical Center, PA, USA.

Extrarenal rhabdoid tumors have been described in a variety of primary sites with only rare case reports of urothelial carcinomas with rhabdoid features in the literature. In this report, we describe the clinicopathologic characteristics, including clinical follow-up on 6 cases of urothelial carcinoma with prominent rhabdoid features. Four cases were retrieved from the consultation files of one of the authors and 2 were retrieved from the surgical pathology files at our institution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2005.10.002DOI Listing
February 2006
5 Reads

Usefulness of immunohistochemistry in delineating renal spindle cell tumours. A retrospective study of 31 cases.

Histopathology 2004 May;44(5):462-71

Division of Pathology and Laboratory Medicine, Loma Linda University Medical Center, Loma Linda, CA 92354, USA.

Aims: To assess the usefulness of immunohistochemistry in delineating tumour diagnoses on a series of morphologically diagnosed renal spindle cell tumours (RSCTs).

Methods And Results: Formalin-fixed paraffin-embedded tissues from 31 morphologically diagnosed tumours were reinterpreted in light of newly obtained immunohistochemical information. By morphology, six had originally been classified as sarcomatoid carcinoma, five as spindle cell tumour (NOS), four as sarcoma (NOS), three as leiomyoma, three as leiomyosarcoma, and one each as fibrous polyp, hamartoma, neurilemmoma, mesoblastic nephroma, medullary fibroma, angiomyolipoma, haemangiopericytoma, malignant rhabdoid tumour, malignant Triton tumour, and carcinosarcoma. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/j.1365-2559.2004.01868.x
Publisher Site
http://dx.doi.org/10.1111/j.1365-2559.2004.01868.xDOI Listing
May 2004
12 Reads

Adult rhabdoid renal cell carcinoma.

Arch Pathol Lab Med 2002 Dec;126(12):1506-10

Tissugen Pty Ltd, Perth, Western Australia.

Background: Pediatric rhabdoid tumor of the kidney is regarded as a distinct neoplasm, whereas rhabdoid differentiation in adult renal cell carcinoma is usually found in association with conventional (clear cell) tumor, from which it is thought to evolve.

Objective: To further characterize the rhabdoid phenotype in adult renal cell carcinoma and to determine its origin by genetic analysis.

Design: We performed histologic, immunophenotypic, and genetic analyses on 5 cases of adult renal cell carcinoma with rhabdoid differentiation, 3 samples of adjacent conventional (clear cell) tumor, and 6 conventional (clear cell) control tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1043/0003-9985(2002)126<1506:ARRCC>2.0.CO;2DOI Listing
December 2002
8 Reads

Kidney pathology: current classification of renal cell carcinoma.

Curr Urol Rep 2002 Feb;3(1):25-30

Department of Pathology and Laboratory Medicine, University of California Los Angeles, CHS 13-226, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA.

This report discusses the new cytogenetic classification of renal cell carcinoma (RCC) and its biological and clinical significance. It describes the four major types (clear cell, chromophil, chromophobe, and collecting duct) as well as rarer entities, such as small cell carcinoma, cystic RCC, rhabdoid variant of RCC, and unclassified RCC. Sarcomatoid carcinomas are a diverse group representing high-grade transformation of the other types. Read More

View Article

Download full-text PDF

Source
February 2002
9 Reads

Caecal adenocarcinoma with rhabdoid phenotype: an immunohistochemical and ultrastructural analysis.

Virchows Arch A Pathol Anat Histopathol 1993 ;422(2):179-82

Department of Anatomical Pathology, Royal Melbourne Hospital, Parkville, Victoria, Australia.

A polypoid caecal adenocarcinoma in a 72-year-old female was found microscopically to be composed mainly of rhabdoid cells. Deposits in the liver and lymph nodes had a similar histological appearance to the primary tumour. The rhabdoid cells were typified by abundant eosinophilic cytoplasm, eccentric nuclei and prominent nucleoli. Read More

View Article

Download full-text PDF

Source
May 1993
9 Reads